

## This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Drug delivery</b>			
Dissolving microneedle arrays for delivery of live adenovirus vaccines	<p>A dissolvable microneedle array could be used for transdermal delivery of adenovirus vaccines. Recombinant human adenovirus type 5 vectors expressing chicken ovalbumin or HIV gag polypeptide antigens were formulated as a dry powder and incorporated into the matrix of a dissolvable microneedle array. In mice, skin immunization using the microneedle array led to antigen-specific CD8<sup>+</sup> T cell responses that were comparable to those induced by conventional injection routes for vaccine delivery. Next steps include testing the microneedle arrays on cadaver skin and then in clinical trials.</p> <p>TheraJect Inc. was involved in the study and has the dissolving microneedle arrays in preclinical development to deliver therapeutics and vaccines.</p> <p><b>SciBX 6(6); doi:10.1038/scibx.2013.153</b> Published online Feb. 14, 2013</p>	Microneedle array covered by multiple issued and pending patents; available for licensing from TheraJect	<p>Bachy, V. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 5, 2013; doi:10.1073/pnas.1214449110</p> <p><b>Contact:</b> Linda S. Klavinskis, King's College London School of Medicine, London, U.K. e-mail: <a href="mailto:linda.klavinskis@kcl.ac.uk">linda.klavinskis@kcl.ac.uk</a></p>